{"id":"mg1111-barycela-inj","safety":{"commonSideEffects":[{"rate":null,"effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":null,"effect":"Hematologic abnormalities (thrombocytopenia, leukopenia)"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Depression / neuropsychiatric effects"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"MG1111 combines human serum albumin with interferon alpha to extend half-life and improve pharmacokinetics while maintaining IFN-α's antiviral and immune-activating properties. The albumin fusion allows for less frequent dosing and potentially improved tolerability compared to conventional interferon formulations. This approach leverages interferon's ability to activate natural killer cells and enhance antiviral immunity.","oneSentence":"MG1111 is a recombinant human albumin-fused interferon alpha (IFN-α) fusion protein that enhances antiviral and immunomodulatory activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:12.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B"},{"name":"Chronic hepatitis C"}]},"trialDetails":[{"nctId":"NCT07054099","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years","status":"NOT_YET_RECRUITING","sponsor":"GC Biopharma Corp","startDate":"2026-03","conditions":"Varicella (Chickenpox), Chickenpox Vaccine","enrollment":474},{"nctId":"NCT05664152","phase":"NA","title":"An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years","status":"UNKNOWN","sponsor":"GC Biopharma Corp","startDate":"2023-02","conditions":"Varicella Zoster Virus Infection","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MG1111 (Barycela inj.)","genericName":"MG1111 (Barycela inj.)","companyName":"GC Biopharma Corp","companyId":"gc-biopharma-corp","modality":"Biologic","firstApprovalDate":"","aiSummary":"MG1111 is a recombinant human albumin-fused interferon alpha (IFN-α) fusion protein that enhances antiviral and immunomodulatory activity. Used for Chronic hepatitis B, Chronic hepatitis C.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}